A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF MAINTENANCE THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY

Trial Profile

A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF MAINTENANCE THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2016 Planned End Date changed from 1 Nov 2018 to 1 Nov 2020.
    • 09 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017.
    • 24 Mar 2015 Planned End Date changed from 1 Sep 2018 to 1 Nov 2018, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top